Ion Beam ApplicationsIOBCF 82 EV-to-EBIT is 24.28 as of Jul. 06, 2026, which is 6% below its 10-year median of 25.93. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.57 (Fairly Valued). The stock has 10 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Ion Beam Applications ranks worse than 63.73% on this metric.
Ion Beam Applications (OTCPK:IOBCF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ion Beam Applications's Enterprise Value for the quarter that ended in Dec. 2025 was $508.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ion Beam Applications's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $26.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Ion Beam Applications's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's EV-to-EBIT falls into.
Ion Beam Applications's current Enterprise Value is $644.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ion Beam Applications's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $26.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ion Beam Applications (IOBCF) has a EV-to-EBIT of 24.28 as of Jul. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ion Beam Applications and its competitors. This is near median its historical median of 25.93. According to the industry distribution chart, Ion Beam Applications ranks #297 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 63.7%.
Is Ion Beam Applications' EV-to-EBIT too high?
Ion Beam Applications' current EV-to-EBIT of 24.28 is near median its 10-year median of 25.93. The Medical Devices & Instruments industry median EV-to-EBIT is 18.72. Ion Beam Applications' value of 24.28 is 29.7% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #297 out of 466 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #297 out of 466 companies for EV-to-EBIT. This places Ion Beam Applications in the lower half of its industry. The industry median EV-to-EBIT is 18.72. Ion Beam Applications' value of 24.28 is 29.7% above this benchmark. While the company's 10-year median is 25.93 vs. the industry median of 18.72, Ion Beam Applications has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.72, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current EV-to-EBIT of 24.28 is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current EV-to-EBIT is 24.28, which is near median its own 10-year median of 25.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.57, compared to a current price of $18.86 — trading 1.6% above its estimated fair value. The current EV-to-EBIT is 24.28, which is near median its 10-year median of 25.93 and 29.7% above the Medical Devices & Instruments industry median of 18.72. Ion Beam Applications' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current EV-to-EBIT is 24.28 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of $18.86 is trading 1.6% above its estimated GF Value™ of $18.57.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
EV-to-EBIT: 24.28 (near median its 10-year median of 25.93)
GF Value™: $18.57 vs. price of $18.86 (1.6% above fair value)
Industry Position: 29.7% above the Medical Devices & Instruments median (#297 of 466)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score
Get the complete analysis for IOBCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
